Other Information .
−Removed: Incorporated By Reference
−Removed: Securities Purchase Agreement, dated as of March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc.
−Removed: and the purchaser party thereto.
−Removed: Exhibit to Form 8-K filed on March 9, 2022
−Removed: Registration Rights Agreement, dated as of March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc.
−Removed: and the purchaser party thereto.
−Removed: Exhibit to Form 8-K filed on March 9, 2022
−Removed: Form of Pre-Funded Warrant
−Removed: Exhibit to Form 8-K filed on March 9, 2022
−Removed: Form of Common Stock Warrant .
−Removed: Exhibit to Form 8-K filed on March 9, 2022
−Removed: Agreement to Assign Space Lease dated March 5, 2022 between Brooklyn ImmunoTherapeutics, LLC and Regen Lab USA LLC.
−Removed: Filed herewith
−Removed: Assignment and Assumption of Lease dated March 25, 2022 between Brooklyn ImmunoTherapeutics, LLC and Regen Lab USA LLC
+Added: Incorporated By
+Added: Amended and Restated Executive Employment Agreement, dated as of May 10, 2022, by and between Brooklyn ImmunoTherapeutics, Inc.
+Added: and Andrew Jackson.
+Added: Exhibit 10.1 to Form 8-K filed on May 31, 2022
+Added: Separation Agreement and General Release, dated May 25, 2022, by and between Brooklyn ImmunoTherapeutics, Inc.
+Added: and Howard J.
+Added: Exhibit 10.2 to Form 8-K filed on May 31, 2022
+Added: Torrey Pines Science Center Lease, dated March 31, 2022, between Brooklyn ImmunoTherapeutics, Inc.
+Added: and Torrey Pines Science Center Limited Partnership..
Filed herewith
20 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
+Added: * Management contract or compensation plan or arrangement
+Added: # Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and
+Added: such information is not otherwise disclosed in such exhibit.
+Added: The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S.
+Added: Securities and Exchange Commission or its staff upon request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BROOKLYN IMMUNOTHERAPEUTICS, INC.
−Removed: June 30, 2022
+Added: August 11, 2022
/s/ Andrew Jackson
1 unchanged sentence
Chief Financial Officer
+Added: (on behalf of the Registrant and as Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.